A bill for an act relating to the right to try Act.

HF 320 would establish Iowa's "Right to Try" framework, allowing terminally ill or severely debilitating patients to access investigational drugs, biological products, or devices not yet approved by the FDA. It defines eligibility for patients with terminal illness (after exhausting all FDA-approved treatments) or life-threatening conditions requiring personalized genomic-based therapies. The bill requires detailed written informed consent documents outlining treatment options, potential outcomes (including risks of hastened death), cost liabilities (patients bear all expenses unless a manufacturer contract states otherwise), and impacts on hospice care eligibility. It specifically applies to Iowa residents seeking individualized treatments based on their genetic profile, such as gene therapy or personalized vaccines, under physician recommendation.